Audentes Therapeutics Inc (BOLD) Trading Down 4.2%
Audentes Therapeutics Inc (NASDAQ:BOLD)’s share price fell 4.2% during mid-day trading on Thursday . The stock traded as low as $14.50 and last traded at $14.99, with a volume of 56,348 shares trading hands. The stock had previously closed at $15.64.
Several brokerages have issued reports on BOLD. Piper Jaffray Cos. set a $24.00 price objective on Audentes Therapeutics and gave the company a “buy” rating in a research report on Wednesday. Cowen and Company began coverage on Audentes Therapeutics in a research report on Monday, August 15th. They issued an “outperform” rating for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 price objective on shares of Audentes Therapeutics in a research report on Thursday.
The company’s 50 day moving average is $14.98 and its 200-day moving average is $14.98. The stock’s market capitalization is $32.69 million.
In related news, Director Orbimed Advisors Llc purchased 33,334 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, July 25th. The shares were acquired at an average price of $15.00 per share, with a total value of $500,010.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Versant Ventures Iv, Llc purchased 35,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, July 25th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $525,000.00. The disclosure for this purchase can be found here.
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.